Tirzepatide

Tirzepatide is a 39-amino-acid synthetic peptide that simultaneously activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. This dual mechanism represents a paradigm shift from earlier single-receptor incretin therapies, with clinical evidence suggesting additive or synergistic metabolic effects that exceed what either pathway achieves independently.

The inclusion of GIP receptor agonism targets adipose tissue lipid metabolism, central appetite regulation through pathways distinct from GLP-1, and potentiation of insulin secretion through a separate intracellular signaling cascade. Phase 3 clinical data have reported mean body weight reductions of 15–22% in participants with obesity — positioning tirzepatide among the most effective pharmacological interventions studied for metabolic disease.

ROEHN supplies tirzepatide at 99% HPLC-verified purity as a lyophilized powder. Active research programs continue to explore applications beyond weight management, including non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction, and obstructive sleep apnea — reflecting the broad therapeutic potential of dual incretin receptor modulation.